Synthekine Inc., an engineered cytokine therapeutics company, today announced that the company has dosed the first patient in the SYNERGY-101 study. SYNERGY-101 is a global, randomized Phase 2 ...
By enhancing metabolism and oxygen consumption, the device can help burn more calories during and after each session, aiding ...
Preexisting autoimmune diseases are tied to shorter hospital stays and less toxicity risk in patients receiving chimeric ...
As energy costs rise and sustainability targets tighten, CSPs are uniquely positioned to help data center operators optimize ...
US hydrogen fuel cell and electrolyzer developer Plug Power has signed a non-binding Letter of Intent (LOI) with an unnamed ...
AT&T will pay consumers in a class action settlement after data breaches last year, with reports stating that some users could receive up to $7,500. Here's how to receive, eligibility, more details ...
Medpage Today on MSN
Something Off About Recent Heart Failure Stem Cell Trial, Major Journal Admits
A boxed warning now lies at the top of the phase III study, PREVENT-TAHA8, which had reported that an intracoronary infusion ...
In a DNA sequence, an individual carries two copies of the genetic material – one from the mother, one from father. If one is ...
Jonny Coker reports for the Southern New Mexico Journalism Collaborative on new data showing effects of smart phone policy in ...
New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in ...
During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback